COMP <GO>
GRDN vs PETS // 10Y YIELD & FRED MACRO BETA
Guardian Pharmacy Services Inc. (Class A) (NYSE) VS. PetMed Express Inc. (NASDAQ) • 15-METRIC TALLY: GRDN 8
— PETS 2
■ METRIC PARITY
LAST: $40.45 (+0.30%) • MKT CAP: $2.56B
macro-sensitivity
—
LAST: $1.18 (-0.84%) • MKT CAP: $25.6M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRDN VS. PETS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRDN | PETS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 20.20% | 28.10% | -7.90 | PETS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 37.70% | -35.00% | +72.70 | GRDN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.91% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 5.00% | -32.80% | +37.80 | GRDN | /operating-margins <GO> |
| Net Profit Margin | 3.40% | -32.00% | +35.40 | GRDN | /net-margins <GO> |
| Revenue Growth (YoY) | 17.90% | -21.10% | +39.00 | GRDN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.08% | -0.08 | PETS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.39 | 0.24 | +12.15 | GRDN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 2/9 | +5.00 | GRDN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.6 | 34.1 | +16.46 | GRDN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 43.8x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.56B | $25.6M | $2.54B | GRDN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRDN REV | PETS REV | GRDN GROSS % | PETS GROSS % | GRDN FCF | PETS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.45B | $179.0M | 20.2% | 28.1% | $100.3M | -$33.0M |
| FY 2024 | $1.23B | $227.0M | 19.9% | 30.5% | $58.0M | -$395.0K |
| FY 2023 | — | $274.1M | — | — | — | $4.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRDN // BETA —
PETS // BETA —